Inventor · disambiguated record
Kyle Macbeth
Also filed as: KAPELLER-LIBERMANN ROSANA · MACBETH KYLE · MACBETH KYLE J · MACBETH KYLE JAMES
26 granted patents·49 pending applications·172 citations·filing 1997–2023
96Inventor score
Files withMILLENNIUM PHARM INC38CELGENE CORP23AGIOS PHARMACEUTICALS INC2BAYER HEALTHCARE AG1CELGENE QUANTICEL RES INC1
Top patents by PatentIndex Score
75 records- 0197US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0294US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 0392US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 0490US11241423B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 8, 2022·2 cites·6 claims
- 0589US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0688US10245258B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2017·Granted Apr 2, 2019·8 cites·43 claims
- 0787US7301016B2Human transferase family members and uses thereofMILLENNIUM PHARM INC·Filed 2002·Granted Nov 27, 2007·14 cites·10 claims
- 0886US7485308B226199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2006·Granted Feb 3, 2009·5 cites·10 claims
- 0984US9125884B2Methods for treating cancers using oral formulations of cytidine analogsCELGENE CORP·Filed 2012·Granted Sep 8, 2015·3 cites·22 claims
- 1082US8841277B2Methods for treating non-small cell lung cancer using 5-azacytidineCELGENE CORP·Filed 2013·Granted Sep 23, 2014·5 cites·34 claims
- 1180US10695352B2Combination therapy for treating malignanciesCELGENE CORP·Filed 2016·Granted Jun 30, 2020·4 cites·15 claims
- 1279US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 1376US6300092B1Methods of use of a novel lysyl oxidase-related proteinMILLENNIUM PHARM INC·Filed 1999·Granted Oct 9, 2001·39 cites·17 claims
- 1476US2023158009A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2023·Application pending·0 cites
- 1574US10653710B2Combination therapy for treating malignanciesAGIOS PHARMACEUTICALS INC·Filed 2016·Granted May 19, 2020·2 cites·20 claims
- 1674US9693987B2Methods for treating cancers using oral formulations of cytidine analogsCELGENE CORP·Filed 2015·Granted Jul 4, 2017·1 cites·21 claims
- 1773US7071004B114094, a novel human trypsin family member and uses thereofMILLENNIUM PHARM INC·Filed 2001·Granted Jul 4, 2006·2 cites·11 claims
- 1873US6872811B1HRPCa9 and HRPCa10 nucleic acids and polypeptidesMILLENNIUM PHARM INC·Filed 1998·Granted Mar 29, 2005·21 cites·10 claims
- 1970US2011020798A1Novel italy, LOR-2, strife, trash, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses thereforMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 2068US11590117B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 2168US7098015B227875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Granted Aug 29, 2006·2 cites·9 claims
- 2267US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 2366US9101579B2Inhibition of drug resistant cancer cellsCELGENE CORP·Filed 2013·Granted Aug 11, 2015·0 cites·6 claims
- 2465US2008248477A1Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses thereforMILLENNIUM PHARM INC·Filed 2007·Application pending·0 cites
- 2565US2010136010A1Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2008·Application pending·0 cites
- 2665US2004176296A1Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses thereforMILLENNIUM PHARM INC·Filed 2004·Application pending·0 cites
- 2764US2018221361A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Application pending·0 cites
- 2864US2010150901A126199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2008·Application pending·0 cites
- 2963US2008108093A1Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2007·Application pending·0 cites
- 3063US2008113399A1Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2007·Application pending·0 cites
- 3159US7235634B22786, a novel human aminopeptidaseBAYER HEALTHCARE AG·Filed 2004·Granted Jun 26, 2007·0 cites·7 claims
- 3259US2004005664A1Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 3359US2019175573A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2019·Application pending·0 cites
- 3459US2004248160A1Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2004·Application pending·0 cites
- 3558US2006009632A1Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2005·Application pending·0 cites
- 3657US2004033509A1Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 3756US2003224417A114400, 2838, 14618, 15334, 14274, 32164, 39404, 38911, 26904, 31237, 18057, 16405, 32705, 23224, 27423, 32700, 32712 and 12216, novel seven-transmembrane proteins/G-protein coupled receptorsMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 3856US2009068187A1Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2007·Application pending·0 cites
- 3956US2003157082A1Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 moleculesMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 4055US2002072089A1Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses thereforFiled 2001·Application pending·0 cites
- 4155US2008051322A114400, 2838, 14618, 15334, 14274, 32164, 39404, 38911, 26904, 31237, 18057, 16405, 32705, 23224, 27423, 32700, 32712 and 12216, novel seven-transmembrane proteins/G-protein coupled receptorsMILLENNIUM PHARM INC·Filed 2007·Application pending·0 cites
- 4254US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 4353US2007087375A1Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710MILLENNIUM PHARM INC·Filed 2006·Application pending·0 cites
- 4453US2014357567A1Methods for treating cancers using oral formulations of cytidine analogsCELGENE CORP·Filed 2014·Application pending·0 cites
- 4553US2003138865A1Nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancerMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 4652US2022378773A1Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapiesCELGENE CORP·Filed 2020·Application pending·0 cites
- 4752US2020405737A1Combination therapy for treating malignanciesAGIOS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4852US2002127694A12786, a novel human aminopeptidaseMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 4952US2007009433A114094, a novel human trypsin family member and uses thereofMILLENNIUM PHARM INC·Filed 2006·Application pending·0 cites
- 5050US5932422AModulation of drug resistance via ubiquitin carboxy-terminal hydrolaseMILLENNIUM PHARM INC·Filed 1997·Granted Aug 3, 1999·10 cites·27 claims
Showing the top 50 of 75 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →